



FORM PTO-147A and B (Modified)		APPLICATION NO.: 09/341,829	ATTY. DOCKET NO.: L0461.70066US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: October 18, 1999	CONFIRMATION NO.: 5643
		APPLICANT: LETHE et al.	
		GROUP ART UNIT: 1642	EXAMINER: Minh Tam B. Davis
Sheet	1	of	1

FOREIGN PATENT DOCUMENTS

Examiner's Initials†	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
th	B1	CA	2346942	A1	Boehringer Ingelheim International GmbH	04-27-2000	Y
	B2	EP	1001022	A1	Boehringer Ingelheim International GmbH	05-17-2000	Y
	B3	EP	1121435	A1	Boehringer Ingelheim International GmbH	08-08-2001	Y
	B4	JP	2002527109T	A1	Boehringer Ingelheim International GmbH	08-27-2002	Y
	B5	WO	0023584	A1	Boehringer Ingelheim International GmbH	04-27-2000	Y

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
th	C1	SHARMA P. et al., "Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer," <i>Cancer Immun.</i> , December 18, 2003; 3:19.	Y
	C2	ODUNSI K. et al., "NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer," <i>Cancer Res.</i> , September 15, 2003; 63(18):6076-83.	Y
	C3	USENER D. et al., "Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients," <i>Br J Dermatol.</i> , August 2003; 149(2):282-8.	Y
	C4	SLAGER E.H. et al., "CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame," <i>J Immunol.</i> , February 1, 2003; 170(3):1490-7.	Y
	C5	RIMOLDI D. et al., "Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma," <i>J Immunol.</i> , December 15, 2000; 165(12):7253-61.	Y
	C6	MANDIC M. et al. "The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells," <i>Cancer Res.</i> , October 1, 2003; 63(19):6506-15.	Y
	C7	AARNOUDSE C.A., "Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1," <i>Int J Cancer.</i> , July 30, 1999; 30;82(3):442-8.	Y
	C8	LETHE B. et al, "LAGE-1, a new gene with tumor specificity," <i>Int J Cancer.</i> , June 10, 1998; 76(6):903-8.	Y

EXAMINER M.T. DAVIS	DATE CONSIDERED 02/20/04
------------------------	-----------------------------

†EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

ORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/341,829

ATTY. DOCKET NO.: L0461.70066US00

FILING DATE: October 18, 1999

CONFIRMATION NO.: 5643

APPLICANT: LETHE et al.

GROUP ART UNIT: 1642

EXAMINER: Minh Tam B. Davis

Sheet 1 of 1

FOREIGN PATENT DOCUMENTS

Examiner's initials†	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
✓	B1	CA	2346942	A1	Boehringer Ingelheim International GmbH	04-27-2000	Y
	B2	EP	1001022	A1	Boehringer Ingelheim International GmbH	05-17-2000	Y
	B3	EP	1121435	A1	Boehringer Ingelheim International GmbH	08-08-2001	Y
	B4	JP	2002527109T	A1	Boehringer Ingelheim International GmbH	08-27-2002	Y
✓	B5	WO	0023584	A1	Boehringer Ingelheim International GmbH	04-27-2000	Y

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
✓	C1	SHARMA P. et al., "Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer," <i>Cancer Immun.</i> , December 18, 2003; 3:19.	Y
	C2	ODUNSI K. et al., "NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer," <i>Cancer Res.</i> , September 15, 2003; 63(18):6076-83.	Y
	C3	USENER D. et al., "Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients," <i>Br J Dermatol.</i> , August 2003; 149(2):282-8.	Y
	C4	SLAGER E.H. et al., "CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame," <i>J Immunol.</i> , February 1, 2003; 170(3):1490-7.	Y
	C5	RIMOLDI D. et al., "Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma," <i>J Immunol.</i> , December 15, 2000; 165(12):7253-61.	Y
	C6	MANDIC M. et al., "The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells," <i>Cancer Res.</i> , October 1, 2003; 63(19):6506-15.	Y
	C7	AARNOUDSE C.A., "Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1," <i>Int J Cancer.</i> , July 30, 1999; 30(82(3):442-8.	Y
	C8	LETHE B. et al., "LAGE-1, a new gene with tumor specificity," <i>Int J Cancer.</i> , June 10, 1998; 76(6):903-8.	Y

EXAMINER

M T DAVIS

DATE CONSIDERED

02/20/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

02/23/04

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/341,829		DOCKET NO.: L0461.70066US00	
				FILING DATE: October 18, 1999		CONFIRMATION NO.: 5643	
				APPLICANT: LETHE et al.			
				GROUP ART UNIT: 1642		EXAMINER: Minh Tam B. Davis	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
JS	A1	6,140,050	B1	Sahin, et al.	10/31/2000
	A2	6,251,603	B1	Jäger, et al.	06/26/2001
	A3	6,252,052	B1	Stockert, et al.	06/26/2001
	A4	6,274,145	B1	Chen, et al.	08/14/2001
	A5	6,338,947	B1	Sahin, et al.	01/15/2002
	A6	6,417,165	B1	Valmori, et al.	07/09/2002
	A7	6,525,177	B2	Stockert, et al.	02/25/2003
	A8	6,605,711	B1	Valmori, et al.	08/12/2003
	A9	6,689,742	B1	Cerundolo, et al.	02/10/2004
	*A10	5,342,774		Boon, et al.	08/30/1994
	*A11	5,405,940		Boon, et al.	04/11/1995

FOREIGN PATENT DOCUMENTS

Examiner's Initials†	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*B7	WO	96/10577		Ludwig Inst. for Cancer Research	04/11/1996	Y
	B8	WO	98/14464		Ludwig Inst. for Cancer Research		

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
JS	C9	Chen, et al., "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening," Proc. Nat'l. Acad. Sci. USA Vol. 94 pgs.:1914-1918 (March 1997)	
	C10	Hillier, EMBL Database, Accession No. AA634317 (Oct. 1997)	
	*C11	Traversari, et al., Immunogenetics 35:145 (1992)	
	*C12	Van der Bruggen, et al. Science 254:1643-1647 (1991)	
	*C13	Rammensee, et al., Immunogenetics 41:178-228 (1995)	
	*C14	Van den Eynde, et al., Curr. Opinion in Immun. 7:674-681 (1995)	
	*C15	De Plaen et al., Immunogenetics 40:360-369, (1994)	
	*C16	Coulie et al., Stem Cells 13:393-403, (1995)	
	*C17	Hubank and Schatz, Nucl. Acids Res. 22:5640, (1994)	

EXAMINER	M. T. DAVIS	DATE CONSIDERED	02/25/04
----------	-------------	-----------------	----------

†EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 08/791,495, filed 01/27/1997, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

02/23/04

ORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 09/341,829		ATTY. DOCKET NO.: L0461.70066US00	
		FILING DATE: October 18, 1999		CONFIRMATION NO.: 5643	
		APPLICANT: LETHE et al.			
		GROUP ART UNIT: 1642		EXAMINER: Minh Tam B. Davis	
Sheet	1	of	1		

FOREIGN PATENT DOCUMENTS

Examiner's Initials†	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
rl	B1	CA	2346942	A1	Boehringer Ingelheim International GmbH	04-27-2000	Y
	B2	EP	1001022	A1	Boehringer Ingelheim International GmbH	05-17-2000	Y
	B3	EP	1121435	A1	Boehringer Ingelheim International GmbH	08-08-2001	Y
	B4	JP	2002527109T	A1	Boehringer Ingelheim International GmbH	08-27-2002	Y
	B5	WO	0023584	A1	Boehringer Ingelheim International GmbH	04-27-2000	Y

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
rl	C1	SHARMA P. et al., "Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer," <i>Cancer Immun.</i> , December 18, 2003; 3:19.	Y
	C2	ODUNSI K. et al., "NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer," <i>Cancer Res.</i> , September 15, 2003; 63(18):6076-83.	Y
	C3	USENER D. et al., "Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients," <i>Br J Dermatol.</i> , August 2003; 149(2):282-8.	Y
	C4	SLAGER E.H. et al., "CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame," <i>J Immunol.</i> , February 1, 2003; 170(3):1490-7.	Y
	C5	RIMOLDI D. et al., "Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma," <i>J Immunol.</i> , December 15, 2000; 165(12):7253-61.	Y
	C6	MANDIC M. et al., "The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells," <i>Cancer Res.</i> , October 1, 2003; 63(19):6506-15.	Y
	C7	AARNOUDSE C.A., "Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1," <i>Int J Cancer.</i> , July 30, 1999; 30;82(3):442-8.	Y
	C8	LETHE B. et al., "LAGE-1, a new gene with tumor specificity," <i>Int J Cancer.</i> , June 10, 1998; 76(6):903-8.	Y

EXAMINER	DATE CONSIDERED
----------	-----------------

†EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).